The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Novo Nordisk is betting on the future with a $2-billion deal to buy rights to a Chinese obesity drug. But investors remain unimpressed.

The United Laboratories, Novo Nordisk ink exclusive global license agreement for UBT251: Guangdong, China Wednesday, March 26, 2025, 10:00 Hrs [IST] The United Laboratories Intern ...

The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.